Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
Featured Articles
(Janssen) Jan 28, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the most common form of...
Read Article
(Wall Street Journal) Jan 15, 2019 - The health-care industry is preparing for a new law that researchers say will mean more treatments for pediatric cancers, which are the leading cause of death from disease among children. The legislation, which requires pharmaceuticals companies to test potential cancer drugs on children as well as...
Read Article
Latest Articles
February 15, 2019
February 15, 2019
February 12, 2019
February 12, 2019
February 08, 2019
February 05, 2019
February 01, 2019
January 31, 2019
View More
News Commentary
Editor Image
09 Jul, 2018 | by Winston Wong, PharmD
The math is simple. Under the proposed agreement, we pay for all doses of the...
View Comment
Editor Image
05 Apr, 2018 | by Winston Wong, PharmD
From a payer perspective, the CMS approval for coverage means that...
View Comment
View More
OBR Blog
As the ASH Annual Meeting concludes, the late-breaking abstracts are always of great interest. We take a brief look at... Read more
December 04, 2018
As the 2018 American Society of Hematology (ASH) Annual Meeting continues, we focus on two studies that have the... Read more
December 04, 2018